Literature DB >> 26421804

High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy.

Steve Innes1, Kameelah L Abdullah, Richard Haubrich, Mark F Cotton, Sara H Browne.   

Abstract

BACKGROUND: Data describing the true extent of antiretroviral therapy (ART)-induced dyslipidemia and insulin resistance in perinatally infected children on ART in Africa are sparse.
METHODS: Fasting total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, insulin and glucose were performed on the first 100 of 190 pediatric ART clinic attendees. Diet assessment was performed by a trained dietician. Lipoatrophy was formally graded by consensus between 2 expert HIV pediatricians. Durations of previous ART exposures, clinical stage, pre-ART viral load, nadir and current CD4 were recorded. Dual-energy X-ray absorptiometry was performed on a subset of 42 patients selected semi-randomly.
RESULTS: Prevalences of insulin resistance, abnormal total cholesterol, LDL, HDL and triglyceride were 10%, 13%, 12%, 13% and 9%, respectively. Overall, 40% had at least 1 lipid abnormality or insulin resistance. Adjusted mean LDL cholesterol increased by 0.24 mmol/L for each additional year of cumulative lopinavir/r exposure (P = 0.03) after correcting for age, gender, body mass index, previous stavudine exposure, age at ART initiation, dietary fat and refined carbohydrate, whereas adjusted mean LDL cholesterol was 0.9 mmol/L higher in children exposed to efavirenz within the previous 6 months (P = 0.02). Adjusting for age, gender and ethnicity, dual-energy X-ray absorptiometry revealed that greater trunk fat and lower peripheral subcutaneous fat were associated with elevated triglycerides but not with total cholesterol, LDL, HDL or homeostatic model assessment. Similarly, the presence of visually obvious lipoatrophy was associated with elevated triglycerides but not with total cholesterol, LDL, HDL, homeostatic model assessment or lactate.
CONCLUSIONS: Prevalences of insulin resistance and dyslipidemia were high. Cumulative lopinavir is an independent risk factor for dyslipidemia, with efavirenz exposure having only transitory effect.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26421804      PMCID: PMC4707556          DOI: 10.1097/INF.0000000000000927

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  24 in total

1.  Diagnosing insulin resistance in the general population.

Authors:  K A McAuley; S M Williams; J I Mann; R J Walker; N J Lewis-Barned; L A Temple; A W Duncan
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

2.  American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood.

Authors:  Rae-Ellen W Kavey; Stephen R Daniels; Ronald M Lauer; Dianne L Atkins; Laura L Hayman; Kathryn Taubert
Journal:  J Pediatr       Date:  2003-04       Impact factor: 4.406

3.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

4.  Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.

Authors:  Marta Beregszaszi; Catherine Dollfus; Martine Levine; Albert Faye; Samia Deghmoun; Nassima Bellal; Muriel Houang; Didier Chevenne; Régis Hankard; Jean-Louis Bresson; Stéphane Blanche; Claire Levy-Marchal
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

5.  Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.

Authors:  Karin Hartman; Gwenda Verweel; Ronald de Groot; Nico G Hartwig
Journal:  Pediatr Infect Dis J       Date:  2006-05       Impact factor: 2.129

6.  An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.

Authors:  A Carr; S Emery; M Law; R Puls; J D Lundgren; W G Powderly
Journal:  Lancet       Date:  2003-03-01       Impact factor: 79.321

Review 7.  What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection.

Authors:  Phyllis C Tien; Carl Grunfeld
Journal:  Curr Opin Infect Dis       Date:  2004-02       Impact factor: 4.915

8.  Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Authors:  Linda Aurpibul; Thanyawee Puthanakit; Benjamin Lee; Ampica Mangklabruks; Thira Sirisanthana; Virat Sirisanthana
Journal:  Antivir Ther       Date:  2007

9.  Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.

Authors:  Mutsawashe Bwakura-Dangarembizi; Victor Musiime; Alexander J Szubert; Andrew J Prendergast; Zvenyika A Gomo; Margaret J Thomason; Cuthbert Musarurwa; Peter Mugyenyi; Patricia Nahirya; Adeodata Kekitiinwa; Diana M Gibb; Ann S Walker; Kusum Nathoo
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

10.  Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy.

Authors:  Agnieszka B Dzwonek; Margaret S Lawson; Tim J Cole; Vas Novelli
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

View more
  18 in total

Review 1.  Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.

Authors:  Todd Hulgan
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.

Authors:  Sahera Dirajlal-Fargo; Victor Musiime; Adrian Cook; Grace Mirembe; Julia Kenny; Ying Jiang; Sara Debanne; Nigel Klein; Grace A McComsey
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 2.129

Review 3.  Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

Authors:  Steve Innes; Kunjal Patel
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

4.  Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda.

Authors:  S Dirajlal-Fargo; L Shan; A Sattar; E Bowman; J Gabriel; M Kulkarni; N Funderburg; R Nazzinda; V Musiime; G A McComsey
Journal:  HIV Med       Date:  2019-10-23       Impact factor: 3.180

5.  Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents.

Authors:  Mitchell E Geffner; Kunjal Patel; Denise L Jacobson; Julia Wu; Tracie L Miller; Rohan Hazra; Mariana Gerschenson; Tanvi Sharma; Margarita Silio; Jennifer Jao; Jody K Takemoto; Russell B Van Dyke; Linda A DiMeglio
Journal:  AIDS       Date:  2018-03-13       Impact factor: 4.177

6.  Insulin Resistance in South African Youth Living with Perinatally Acquired HIV Receiving Antiretroviral Therapy.

Authors:  Lisa J Frigati; Jennifer Jao; Sana Mahtab; Nana-Akua Asafu Agyei; Mark F Cotton; Landon Myer; Heather J Zar
Journal:  AIDS Res Hum Retroviruses       Date:  2018-09-25       Impact factor: 2.205

7.  Mitochondrial Dysfunction and Insulin Resistance in Pubertal Youth Living with Perinatally Acquired HIV.

Authors:  Greg S Gojanovich; Denise L Jacobson; Jennifer Jao; Jonathan S Russell; Russell B Van Dyke; Daniel E Libutti; Tanvi S Sharma; Mitchell E Geffner; Mariana Gerschenson
Journal:  AIDS Res Hum Retroviruses       Date:  2020-07-20       Impact factor: 2.205

8.  Unique circulating microRNA associations with dysglycemia in people living with HIV and alcohol use.

Authors:  Brianna L Bourgeois; Hui-Yi Lin; Alice Y Yeh; Danielle E Levitt; Stefany D Primeaux; Tekeda F Ferguson; Patricia E Molina; Liz Simon
Journal:  Physiol Genomics       Date:  2021-12-03       Impact factor: 4.297

Review 9.  Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.

Authors:  Sahera Dirajlal-Fargo; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-15       Impact factor: 5.495

10.  APOC3 Gene Polymorphism and Antiretroviral Therapy-Induced Dyslipidemia in HIV-Infected Children.

Authors:  Ramalingam Srinivasan; Chandrasekaran Padmapriyadarsini; Karunaianantham Ramesh; G N Sanjeeva; Devarajulu Reddy; Elumalai Suresh; Ramesh Kumar; Pattabiraman Sathyamoorthy; Soumya Swaminathan; Anita Shet
Journal:  AIDS Res Hum Retroviruses       Date:  2020-11-26       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.